Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b ...
New late-breaking data to be presented today by the Australian and New Zealand Urogenital and Prostate (ANZUP) Clinical ...
IMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profileIMA402 achieved a cORR of 32%, 12.5 months median DOR and ...
Incyte (Nasdaq:INCY) and Genmab A/S (Nasdaq:GMAB) today announced a clinical trial collaboration to evaluate INCB161734, ...
Palvella Therapeutics (NasdaqGM:PVLA) reported positive Phase 3 SELVA trial results for QTORIN rapamycin in microcystic ...
Zolucatetide continued to demonstrate a favorable safety and tolerability profile at the selected doses for Phase 3 registrational development Treatment-related adverse events (TRAEs) were ...
In 24 heavily pre-treated patients with advanced primary cutaneous melanoma whose cancer had progressed after multiple prior lines of therapy ...
A UK modified Delphi consensus of 19 experts has produced 22 statements recommending that patients with spinal muscular ...
Newspoint on MSN
Cancer: diagnoses rise across India. what drives it?
Recent national health reports have highlighted a concerning upward trend in cancer diagnoses across India, prompting renewed ...
Altimmune's stock fell 7.57% on October 24, 2026, with a 40.52% annual loss amid investor concerns over financial health and clinical pipeline risks.
A new review of thirty studies finds artificial intelligence showing strong potential across minimally invasive vascular ...
COCOON shows lazertinib lead-in plus simplified prophylaxis reduced grade ≥2 skin toxicity to 18% with SC amivantamab in EGFR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results